INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19

INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19

PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechno...
read more
Sanofi and GSK to provide 72 million vaccine doses to Canada

Sanofi and GSK to provide 72 million vaccine doses to Canada

French pharmaceutical firm Sanofi and Britain&#821...
read more
UK reserves up to 190 mn vaccine doses from Valneva

UK reserves up to 190 mn vaccine doses from Valneva

Britain has secured access to up to 190 million do...
read more
At high doses, popular biotin supplement could mask heart trouble

At high doses, popular biotin supplement could mask heart trouble

(HealthDay)—A growing number of older people are...
read more
Popular supplement may protect multiple generations from Alzheimer’s

Popular supplement may protect multiple generations from Alzheimer’s

High doses of a nutrient found in meat, eggs and f...
read more